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Insertion ofQ:1; 2; 3 N-Terminal Hinge Glycosylation Enhances
InteractionsQ:4; 5; 6 of the Fc Region of Human IgG1 Monomers to
Glycan-DependentQ:7; 8; 9 Receptors and Blocks Hemagglutination
by the Influenza VirusQ:10
Patricia A. Blundell,* Dongli Lu,† Mark Wilkinson,* Anne Dell,† Stuart Haslam,† and
Richard J. Pleass*
In therapeutic applications in which the Fc of IgG is critically important, the receptor binding and functional properties of the Fc are
lost after deglycosylation or removal of the unique Asn297 N-X-(T/S) sequon. A population of Fcs bearing sialylated glycans has
been identified as contributing to this functionality, and high levels of sialylation also lead to longer serum retention times
advantageous for therapy. The efficacy of sialylated Fc has generated an incentive to modify the unique N-linked glycosylation
site at Asn297, either through chemical and enzymatic methods or by mutagenesis of the Fc, that disrupts the protein–Asn297
carbohydrate interface. In this study, we took an alternative approach by inserting or deleting N-linked attachment sites into the
body of the Fc to generate a portfolio of mutants with tailored effector functions. For example, we describe mutants with enhanced
binding to low-affinity inhibitory human Fcg and glycan receptors that may be usefully incorporated into existing Ab engineering
approaches to treat or vaccinate against disease. The IgG1 Fc fragments containing complex sialylated glycans attached to the
N-terminal Asn221 sequon bound influenza virus hemagglutinin and disrupted influenza A–mediated agglutination of human
erythrocytes. The Journal of Immunology, 2019, 202: 000–000.
M
ultipleQ:12 lines; 13 of evidence have shown that glycosylation
is critical to driving either the anti- or proinflammatory
capability of IgG (1). Glycosylation of the only
available carbohydrate attachment site (Asn297) in the Fc is es-
sential for interactions with type 1 receptors (Fcg) and type 2
receptors (glycan dependent) but also for driving interactions with
the complement cascade (2–5).
In humans, infusion of Fc fragments is sufficient to ameliorate
idiopathic thrombocytopenic purpura in children, demonstrating
the therapeutic use of the Fc in vivo (6). These anti-inflammatory
properties of the Fc are lost after deglycosylation of IgG, and a
population of IgG-bearing sialylated Fcs has been identified as
making a significant contribution to the control of inflammation in
animal models (7, 8). Higher levels of sialylation also leads to
longer serum retention times (9, 10), and studies in humans and
mice have shown that influx and efflux of IgG into the CNS is
glycan and sialic acid dependent (11–16).
Consequently, the efficacy of sialylated Fc has generated an
incentive to modify the existing glycans on Asn297, either by
chemical means or through mutagenesis programs in the Fc pro-
tein backbone that disrupt the protein–Asn297–carbohydrate in-
terface (17–19). However, chemical modification of pre-existing
glycans is expensive and reliant on a sustainable source of human
Fc, whereas mutagenesis approaches on the Fc, or expression in
glycosidase-deficient/transgenic cell lines, have yielded little im-
provement in Asn297 sialylation to the levels required for signifi-
cant enhancements in the affinity of binding to FcgRs (18, 19).
Recently, coadministration of two glycosyltransferase Fc-fusion
proteins has been shown to convert endogenous IgG into sialy-
lated anti-inflammatory IgGs that attenuate autoimmune disease in
animal models in a platelet-dependent manner (20). Although
in vivo enzymatic sialylation may circumvent many technical is-
sues concerned with chemical or mutagenic approaches to gen-
erating sialylated IgG, it may not be appropriate in all clinical
settings, for example in neurologic diseases (e.g., neuromyelitis
optica) in which the target site is mostly devoid of platelets and in
which two different Fc fusions would need to traverse the blood–
brain barrier simultaneously. This approach also runs the risk of
off-target glycan modifications and known immunogenicity of
long-term administration of Fc fusions (21).
Mutagenesis studies to date have also been limited in two further
respects. Side-chain changes have typically been restricted to al-
anine or serine, and functionality studies havemostly been confined
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to FcgR-binding studies (22, 23). It is therefore of academic in-
terest and potential clinical value to explore more thoroughly how
the introduction of additional N-glycan sites into the Fc might
affect changes in binding to FcgR and other atypical Fc glycan
receptors, including sialic acid–binding Ig-type lectin (Siglecs)
and C-type lectins.
We recently published two complementary approaches that
radically increase the sialic acid content of the Fc (24) first by
insertion of the 18-aa tailpiece from IgM onto the C terminus of
the IgG1–Fc into which a cysteine-to-alanine substitution is made
at Cys575 and second by the addition of an extra N-glycan to the N
terminus at position Asn221. This approach resulted in both mul-
timeric and monomeric molecules that are .75% sialylated
(compared with 2% for the IgG–Fc control) that bind to sialic
acid–dependent receptors, including Siglec-1 and myelin-
associated glycoprotein (MAG) (24), which are clinically impli-
cated in the control of neuropathologyQ:14 (15, 25). As many patho-
gens rely on glycans to infect host cells, these reagents may also
be useful as inhibitors of infection (26).
The human IgG1–Fc typically does not bind glycan receptors
because the glycan attached to Asn297 is largely buried within the
cavity formed by the CH2-CH3 homodimer (27, 28). The location
and content of glycans attached at Asn297 also modulates the af-
finity of the Fc for binding to the classical FcgRs through con-
formational changes imparted to the FcgR-binding region located
in the lower hinge (29). In this article, we show that these limi-
tations to Asn297-directed receptor binding can be overcome
through a program of mutagenesis aimed at disrupting disulfide
bonding while enhancing N-linked glycosylation within the IgG1
Fc (Figs. 1, 2).
To this end, we created two panels of human IgG1 Fc mutants
(Figs. 1, 2) by deleting critical disulfide bonds and/or by inserting
or deleting N-linked asparagine attachment sites located within the
previously described IgG1–Fc multimer (2, 5, 24, 30). This ap-
proach not only yielded molecules with enhanced binding to low-
affinity FcgRs but also showed interactions with receptors not
previously known to bind the IgG1 Fc, including Siglec-1, Siglec-
2, Siglec-3, Siglec-4, CD23, Dectin-1, Dectin-2, CLEC-4A (C-
type lectin dendritic cell immunoreceptor [DCIR]), CLEC-4D,
F1
F2
FIGURE 1. Schematic showing the various hexa-Fc glycan mutants in which Cys575 is mutated to alanine to create the C575A panel of mutants. Red
stars indicate the hinge Asn221, the Cg2 Asn297, and the tailpiece Asn563 glycan sitesQ:41 .

































































































































macrophage mannose receptor (MMR), mannose-binding lectin
(MBL), and DEC-205. Finally, we were able to identify mono-
meric Fc glycan mutants with enhanced binding to influenza A
virus hemagglutinin (HA) that inhibited viral-mediated aggluti-
nation of human erythrocytes.
Materials and Methods
Production of mutants
The generation of glycan mutants in all combinations has been described
previously for the hexa-Fc that contains cysteines at both positions 309 and
575 (24). To make the new mutants described in Fig. 1 in which Cys575 was
mutated to alanine, PCR overlap extension mutagenesis was used with a
pair of internal mismatched primers 59-ACCCTGCTTGCTCAACTCT-39 /
39-GGCCAGCTAGCTCAGTAGGCGGTGCCAGC-59 for each plasmid
vector coding for a designated glycan modification. The parental plasmids
used for these new PCR reactions have been described previously (24).
The resulting C575A mutants were then further modified to remove Cys309
using primer pair 59-TCACCGTCTTGCACCAGGACT-39 / 39-
AGTCCTGGTGCAAGACGGTGA-59 to create the panel of double cys-
teine knockouts described in Fig. 2. To verify incorporation of the desired
mutation and to check for PCR-induced errors, the open reading frames of
the new mutants were sequenced on both strands using previously de-
scribed flanking primers (24). CHO-K1 cells (European Collection of
Authenticated Cell Q:15Cultures) were transfected with plasmid using FuGene
(Promega), and Fc-secreting cells were cloned, expanded, and the proteins
purified as previously described (2, 30).
Receptor and complement binding assays
Methods describing the binding of mutants to tetrameric human dendritic
cell–specific intercellular adhesion molecule-3–grabbing nonintegrin (DC-
SIGN; Elicityl), Siglec-1, Siglec-4, and Siglec-3 (Stratech Scientific) have
all been described previously (2, 30). The same ELISA protocol was used
for Siglec-2, CD23, dec-1, dec-2, clec-4a, clec-4d, MBL, and MMR
(Stratech Scientific or Bio-Techne). Binding of C1q and C5b-9 have been
described previously (2, 30). ELISAs were used to investigate binding of
Fc glycan mutants to human FcgRI, FcgRIIA, FcgRIIB, FcgRIIIA, and
FcgRIIIB (Bio-Techne). Receptors were coated down on ELISA plates
(Nunc) in carbonate buffer (pH 9) (Sigma-Aldrich) at 2 mg/ml overnight at
4˚C, unless otherwise specified. The plates were blocked in PBS/0.1%
Tween-20 containing 5% dried skimmed milk. Plates were washed three
times in PBS/0.1% Tween-20 before adding Fc mutant proteins at the
indicated concentrations and left at 4˚C overnight. Plates were washed as
FIGURE 2. Schematic showing the C575A panel of glycan mutants from Fig. 1 in which Cys309 and Leucine310 is additionallyQ:42 changed to leucine and
histidine as found in the native IgG1 Fc sequence to create the C309L/C575A panel of mutants. Red stars indicate the hinge Asn221, the Cg2 Asn297, and the
tailpiece Asn563 glycan sites.

































































































































above and incubated for 2 h with 1:500 dilution of an alkaline phospha-
tase–conjugated goat F(ab9)2 anti-human IgG (The Jackson LaboratoryQ:16 ).
Binding of the secondary detecting Fab’2 anti-human Fc was checked by
direct ELISA to every mutant to ensure there were no potential biases in
the detection of binding of different mutants to different receptors
(Supplemental Fig. 1A). Plates were washed and developed with 100 ml/
well of a SIGMAFASTQ:17 p-nitrophenyl phosphate solution (Sigma-Aldrich).
Plates were read at 405 nm, and data were plotted with GraphPad Prism.
Binding to HA
ELISA plates were coated with 5 mg/ml recombinant HA from different
influenza A and B viruses (BEI Resources) or native influenza A New
Caledonia H1N1 virus (2B Scientific) in carbonate buffer (pH 9) and left at
4˚C overnight. Plates were washed five times with TSMQ:18 buffer (20 mM
Tris-HCl, 150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2) prior to blocking for
2 h in 150 ml/well of TMS buffer containing 5% BSA. After washing as
before, 100 ml of Fc fragments at 30 mg/ml in TSM buffer was added in
triplicate wells. Fc fragments were allowed to bind overnight at 4˚C. Plates
were washed five times with excess TSM buffer prior to the addition of 100
ml/well of alkaline phosphatase–conjugated F(ab9)2 goat anti-human IgG1
Fcg fragment-specific detection Ab diluted 1 in 500 in TMS buffer. Gly-
cosylated Fc fragments that bound to the glycan receptors were left to bind
the conjugated Ab for 1 h at room temperature on a rocking platform.
Plates were washed as above and developed for 10 min with 100 ml/well of
p-Nitrophenyl phosphate. Plates were read at 405 nm using a LT-4500
Microplate Absorbance Reader (Labtech), and the data were plotted with
GraphPad Prism.
Hemagglutination inhibition assay
To determine the optimal virus-to-erythrocyte ratio, 2-fold virus stock (2B
Scientific) dilutions were prepared in U-shaped 96-well plates (Thermo
Fisher Q:19Scientific). The same volume of a 1% human O+ RBC suspension
(Innovative Research) was added to each well and incubated at room
temperature Q:20for 60 min until erythrocyte pellets had formed in the negative
control. After quantifying the optimal virus-to-erythrocyte concentration
(4HA units), serial 2-fold dilutions of Fc, control IVIG (GAMMAGARD,
Baxter Healthcare), or polyclonal goat anti-influenza H1N1 (Bio-Rad
Laboratories Q:21) were prepared, starting at a concentration of 2 mM, and
mixed with 50 ml of the optimal virus dilution. After a 30 min incubation
at 4˚C, 50 ml of the human erythrocyte suspension was added to all wells
FIGURE 3. Characterization of mutant Fc proteins by SDS-PAGE. (A) N563A/C575A and N297A/N563A/C575A form laddered multimers (red arrows)
with folding intermediates (blue arrows) that are different to those formed by the hexa-Fc control. The C575A and N297A/C575A mutants run as
monomers, with dimers and trimers also seen. Removal of Asn563 favors multimerization in the presence of Cys309 but the absence of Cys575. The addition
of a N-X-(T/S) glycan sequon to generate N-terminally glycosylated hinges (the D221N series of mutants) did not affect multimerization but increased the
molecular mass of all mutants. (B) The same mutants as in (A) but run under reducing conditions. (C) The same mutants as in (A) but stained with
Coomassie reagent. The decreasing molecular masses seen in the Fc represent sequential loss of N-linked glycans. The N297A/N563A/C575A mutant has
the smallest molecular mass because it has no glycans attached to the Fc, and D221N/C575A has the largest molecular mass because it has three glycans
attached. The types of glycans attached at Asn221, Asn297, and Asn563 for all mutants are shown in Supplemental Figs. 2–4. (D) Substitution of Cys309 with
leucine onto the mutants shown in (A) to create the double cysteine knockouts, which run as monomers. Differing molecular masses are seen with C309L/
N297A/C575A monomers, which may represent differential glycosylation of Asn563. (E) The same mutants as in (D) but run under reducing conditions. (F)
Coomassie-stainedQ:43 gel of (D). All proteins were run under either nonreducing or reducing conditions at 2 mg protein per lane on a 4–8% acrylamide
gradient gel, transferred to nitrocellulose, and blotted with anti-human IgG Fc (Sigma-AldrichQ:44 ).

































































































































and plates incubated at room temperature for 1 h, after which erythrocyte
pellets could be observed in the positive controls.
N-glycomic analysis
N-glycomic analysis was based on previously developed protocol with
some modifications (31). Briefly, the N-glycans from 50 mg of each sample
were released by incubation with New England BioLabsQ:22 Rapid PNGase F
and isolated from peptides using Sep-Pak C18 cartridges (Waters). The
released N-glycans were permethylated, prior to MALDI mass spectrom-
etryQ:23 analysis. Data were acquired using a 4800 MALDI-TOF/TOF mass
spectrometer (Applied Biosystems) in the positive ion mode. The data
were analyzed using Data Explorer (Applied Biosystems) and Glyco-
Workbench (32). The proposed assignments for the selected peaks were
based on composition together with knowledge of the biosynthetic path-
ways.
Binding to FcgRs by Biacore
Binding to FcgRs was carried out using a Biacore T200 biosensor (GE
Healthcare). Recombinantly expressed FcgRs (R&D systems and Sino
Biological) were captured via their histidine tags onto CM5 chips pre-
coupled with ∼9000 RUQ:24 anti-His Ab (GE Healthcare) using standard
amine chemistry. Fc mutants were injected over captured receptors at a
flow rate of 20 ml/min, and association and dissociation were monitored
over indicated time scales before regeneration with two injections of
glycine (pH 1.5) and recalibration of the sensor surface with running buffer
(10 mM HEPES, 150 mM NaCl [pH 7]). Assays were visualized with
Biacore T200 evaluation software v 2.0.1.
Results
Disulfide bonding and glycosylation influence the
multimerization states of hexa-Fc
To determine the contribution of two N-linked glycosylation sites
(Asn297 and Asn563) and two cysteine residues (Cys309 and Cys575)
in the multimerization of hexa-Fc (2), we created two panels of
glycosylation- and cysteine-deficient mutants by site-directed
mutagenesis, using the previously described hexa-Fc as the tem-
plate (Figs. 1, 2) (2, 24). We also inserted an N-linked attachment
site at the N terminus of the Fc (D221N) to investigate the impact
of additional glycosylation on Fc function (Figs. 1, 2). Following
transfection of these mutated IgG1–Fc DNAs into CHO-K1 cells,
stable clonal cell lines were established, and the secreted Fcs were
purified by protein G affinity chromatography. The purified pro-
teins were analyzed by SDS-PAGE (Fig. 3) and size-exclusion
chromatography (SEC)-HPLC (Supplemental Fig. 1D).
When analyzed under nonreducing conditions (Fig. 3A, 3C and
Supplemental Fig. 1C), the C575A mutant migrated mostly as
monomers (∼55 kDa), with a very small proportion of dimer
(∼110 kDa) and trimer (∼165 kDa). Insertion of a glycan at
Asn221 into the C575A mutant (to create D221N/C575A) resulted
in reduction of the trimer fraction and a decrease in the proportion
of dimers observed, although the molecular weights of each of the
species increased as a consequence of the additional N-terminally
attached Asn221 sugar (Fig. 3A–C, Supplemental Fig. 1C).
Because we had previously shown that removal of the tailpiece
glycan (Asn563) in hexa-Fc led to the formation of dodecamers
(24), we reasoned that a similar mutation introduced into the
C575A mutants would also lead to enhanced dodecamer forma-
tion. Surprisingly, removal of Asn563, as in N563A/C575A,
N297A/N563A/C575A, D221N/N563A/C575A, and D221N/
N297A/N563A/C575A, led to the formation of a laddering pat-
tern of different molecular masses from ∼50 to .500 kDa
(Fig. 3A, red arrows, 3C), representing monomers, dimers,
F3
FIGURE 4. Binding of the C309L and C575A double cysteine IgG1–Fc glycosylation mutants to glycan receptors. Mutants lacking either the N297 and/
or N563 glycans are severely restricted in their capacity to bind glycan receptors as determined by ELISA. The addition of an N-linked sugar at position 221
into the Asn297 and/or Asn563 mutants reinstates binding to all receptors investigated, with the exception of MBL, MMR, and DC-SIGN. Insertion of Asn221
into C309L/C575A enhances interactions to all the glycan receptors investigated. Error bars represent SD around the mean value; n = 2 independent
experiments.

































































































































trimers, tetramers, pentamers, hexamers, etc. Weaker bands be-
tween these species may represent 25 kDa folding intermediates
that include Fc halfmers (Fig. 3A, blue arrows). All proteins in
which the tailpiece Asn563 glycan was substituted for alanine run
as multimers in solution when examined by SEC-HPLC
(Supplemental Fig. 1C).
By running these mutants under reducing conditions, we were
able to determine the relative sizes and occupancy of the glycans
attached at each position, showing that the Asn221 and Asn563
glycans are larger than that at Asn297 and that fully aglycosylated
null mutants such as N297A/N563A/C575A are ∼10 kDa lighter
than either hexa-Fc or C575A glycan-competent molecules
(Fig. 3B).
As Cys309 is present in these mutants (Figs. 1, 3A–C), the
ladders may arise through disulfide bond formation between the
only freely available sulfhydryl at Cys309 in two adjacent
monomers. We reasoned that the loss of the tailpiece glycan in
these four N563A mutants allows the hydrophobic amino acid
residues (Val564, Leu566 and Ile567) also located in the tailpiece to
cluster, thereby permitting disulfide bonding at Cys309.
To test the hypothesis that Cys309 was indeed responsible for
the laddering seen with the N563A-deficient mutants, we gen-
erated a second panel of C575A mutants in which Cys309/Leu310
are mutated to Leu309/His310 as found in the wild-type IgG1 Fc
sequence (Fig. 2). We also generated the mutant CL309-310LH
(C309L) in which the tailpiece Cys575 was still present. This
mutant ran similarly to hexa-Fc under nonreducing conditions,
albeit with the presence of intermediates (Fig. 3D, blue arrows)
that were notably absent in hexa-Fc, showing that Cys309 stabi-
lizes the quaternary structure in the presence of Cys575.
Importantly, the loss of Cys309 also resulted in the loss of the
ladders previously seen in the Cys309-competent mutants
(Fig. 3D, 3F versus 3A, 3C), with all the double cysteine mutants
now running principally as monomers by SDS-PAGE. The
C309L/N297A/C575A mutant runs as four different monomeric
species (Fig. 3D) that resolve as two bands under reduction
(Fig. 3E). These bands may represent glycan variants arising at
Asn563. Given that these variants are absent in the C309L/C575A
mutant, we conclude that the presence of Asn297 glycan also
controls glycosylation efficiency at Asn563. To a degree, the
presence of the Asn221 glycan also limits the occurrence of these
Asn563 glycoforms because under reduction, only a single band is
seen in the D221N/C309L/N297A/C575A mutant (Fig. 3E).
Although the panel of double cysteine knockouts run mostly as
monomers on SDS-PAGE (Fig. 3D, 3F), the double cysteine
knockouts containing the N563A substitution run as a mixture of
monomers and multimers in solution (Supplemental Fig. 1C).
Thus, removal of the bulky Asn563 glycan exposes hydrophobic
amino acid residues in the tailpiece that facilitate noncovalent
interactions in solution that would not otherwise readily occur in
the presence of the sugar.
The Asn297 and Asn563 glycans are critical for the interactions
of mutants with glycan receptors, and their absence can be
compensated by the presence of Asn221
To determine which N-linked glycan in the double cysteine
knockout mutants (Fig. 2) contributes to receptor binding, Q:25we
investigated their interaction with soluble recombinant glycan
receptors by ELISA (Fig. 4, Table I). In stark contrast to the
IgG1–Fc control, mutants in which both Asn297 and Asn563 are
present (e.g., C309L/C575A) bound all 12 glycan receptors in-







































































































































































































































































































































































































































































































































































































































































































































































































































































































































abolished binding to these same receptors, showing that Asn563 is
required for glycan receptor binding.
Removal of the glycan at Asn297, as in C309L/N297A/C575A,
also abolished binding to all glycan receptors with the exception
of Siglec-1. Taken together, the data show that both Asn563 and
Asn297 are required for the broad glycan receptor binding seen
with the C309L/C575A mutant (Fig. 4 and Table I).
With the exception of MBL, MMR, and DC-SIGN, binding by
the double aglycosylated knockout C309L/N297A/N563A/C575A
could be reinstated by the addition of sialylated glycans at Asn221,
creating the mutant D221N/C309L/N297A/N563A/C575A. The
Asn221 glycan contributes all the sialylated sugars that are re-
quired to explain the marked improvements in binding to other
glycan receptors, compared with all equivalent mutants lacking
Asn221 (Supplemental Figs. 2–4). This is in agreement with our
previous work in which we demonstrated in fully cysteine-
competent multimers that Asn221 is .75% terminally sialylated
(24).
The C309L mutant that can form cysteine-linked multimers
because of the retention of Cys575 in the tailpiece (Fig. 3D, 3F and
Supplemental Fig. 1C) was unable to bind to any glycan receptors
with the exception of CD23 (Fig. 4). Thus, the Asn563 glycans are
only available for binding when attached to lower valency mole-
cules and are buried within multimers that form either through
Cys309-driven covalent bridging or by noncovalent clustering
through multiple hydrophobic amino acids located in the tailpiece
(e.g., C309L/N563A/C575A).
We next investigated binding of the panel of C575A mutants in
which Cys309 is still present (Fig. 1) and that we had shown to
have the tendency to form dimers and laddered multimers
(Fig. 3A, 3C and Supplemental Fig. 1C). This panel of molecules,
in which disulfide bonding mediated by Cys309 could still occur,
bound less well to all the glycan receptors investigated (Fig. 5). With
the sole exception of Siglec-1, the presence of the Asn221 glycan was
unable to improve binding, in contrast to the double cysteine
knockouts. We conclude that N-glycans at all three attachment sites
(Asn221, Asn297, and Asn563) are more predisposed to binding to
glycan receptors when expressed on monomers and that the presence
of Asn221 as the only glycan is sufficient to impart this broad spec-
ificity of binding, as exemplified by D221N/N297A/N563A/C575A
and D221N/C309L/N297A/N563A/C575A (Figs. 4, 5).
We observed that the aglycosylated mutant N297A/N563A/
C575A had a propensity to bind glycan receptors (Fig. 5). We
do not have a simple answer for this observation, although the lack
of binding by its counterpart C309L/N297A/N563A/C575A in
which Cys309 Q:26is absent suggests that it may be glycan indepen-
dent and a consequence of increased avidity interactions through
multimerization (compare Fig. 3A v 3D).
Glycan receptor binding is critically dependent on the
presence of N-linked glycans
To be certain that glycan receptor binding was dependent on the
presence of N-linked carbohydrates, and more specifically sialic acid,
these sugars were removed from the triglycan D221N/C309L/C575A
mutant using either PNGase F or neuraminidase (Supplemental Fig.
1B). As expected, the D221N/C309L/C575A mutant treated with
PNGase F was unable to bind any of the receptors investigated,
whereas treatment with neuraminidase inhibited binding to the sialic
acid–dependent receptors (Supplemental Fig. 1B).
F5
FIGURE 5. Binding of C575A mutants to glycan receptors. Proteins with a predisposition to multimerize via Cys309 interactions (as shown in Fig. 3A,
3C, and Supplemental Fig. 1C) are less able to engage glycan receptors than their equivalent mutants in which Cys309 was changed to leucine (Fig. 3D, 3F).
With the exception of Siglec-1, the insertion of Asn221 into mutants that tend to form multimers had no effect on, or was detrimental to, binding of glycan
receptors. Error bars represent SD around the mean value; n = 2 independent experiments.

































































































































FIGURE 6. Binding of C309L (A–C) and the C575A (D–F) glycosylation mutants to classical FcgRs. The D221N/C309L/N563A/C575A mutant shows
enhanced binding to FcgRI, FcgRIIB, and FcgRIIIA, whereas C309L/N563A/C575A only shows enhanced binding to FcgRI and FcgRIIIA. Mutant
N563A/C575Awith a predisposition to multimerize via Cys309 interactions (as shown in Fig. 3A, 3C) binds strongly to FcgRI and FcgRIIIA as is also seen
with C309L/N563A/C575A that carries the same N563A mutation. The D221N/N563A/C575A mutant shows enhanced binding to FcgRI and FcgRIIIA. In
multimers, the presence of Asn221 constrains interactions with FcgRIIB that are enhanced when Asn221 is attached to monomers (E). No improvement in
binding was observed to FcgRIIA or FcgRIIIB for any of the mutants tested (data not shown). Error bars represent SD around the mean value; n = 2
independent experiments.

































































































































Asn221-based monomers show differential binding to
low-affinity human FcgRs
Given the remarkable binding to glycan receptors seen with
some of the glycan-modified mutants, we tested the impact that
this extra glycosylation conferred on binding to the classical
human FcgRs (Fig. 6, Table II). The presence of Asn221, for
example in the D221N/C309L/N297A/N563A/C575A mutant,
imparted improved binding to FcgRIIB (CD32B) even in the ab-
sence of both Asn297 and Asn563 when compared with the IgG1–Fc
and controls in which Asn221 was absent (Fig. 6, for FcgRIIB
compare filled symbols versus unfilled symbols). However, the
presence of Asn221 did not improve binding to FcgRIIIA (compare
D221N/C309L/N563A/C575A and C309L/N563A/C575A), al-
though binding of both mutants was considerably stronger than the
IgG1–Fc monomer control (Figs. 6, 7B). We hypothesize that the
enhanced binding observed with the N563A-deficient mutants is a
consequence of increased tailpiece-mediated assembly by all the
Asn563-deficient proteins (Supplemental Fig. 1C). Improved binding
to FcgRI was also observed with these two mutants against the
IgG1–Fc control (Figs. 6, 7A), although no improvements were
seen with respect to either FcgRIIA or FcgRIIIB for any of the
mutants tested.
Both the double cysteine knockouts, C309L/N563A/C575A and
D221N/C309L/N563A/C575A, that form multimers in solution
and bound FcgRI and FcgRIIIA (Val176) strongly in ELISAs were
tested for binding FcgRs receptors by surface plasmon resonance
analysis (Fig. 7). Both mutants displayed slower apparent off rates
compared with the control Fc monomer, consistent with avidity
effects either through binding to multiple immobilized FcgRs
molecules or rebinding effects (Fig. 7). The loss of Asn297 in the
C309L/N297A/C575A and D221N/C309L/N297A/C575A mu-
tants resulted in molecules that were unable to bind FcgRs, as
previously shown by ELISA (Figs. 6, 7).
We next investigated binding of the multimers formed through
Cys309 (Figs. 1, 3A, 3C). In multimers, the presence of Asn221
reduced binding to all FcgRs (Fig. 6, Table II), whereas binding
to the glycan receptors, although lower than that seen with
monomers, was retained (Fig. 5). Multimers in which Asn563
and Cys575 are both mutated to alanine, as in N563A/C575A,
bound very strongly to FcgRI and FcgRIIIA, with improved
binding to FcgRIIB when compared with either the hexa-Fc or
IgG1–Fc controls (Fig. 6). The aglycosylated multimer N297A/
N563A/C575A bound very well to the inhibitory FcgRIIB recep-
tor while retaining binding to FcgRI (Fig. 6).
Asn221-based monomers and multimers show reduced
complement activation
Binding of C1q and activation of the classical complement pathway
by complex monomers (Fig. 8A) and multimers (Fig. 8B) was
assessed using ELISA and summarized in Table III (24, 30). With
the exception of D221N/C309L/N563A/C575A, all Asn221-con-
taining monomers bound C1q less well than the IgG1–Fc– Q:27or
Asn221-deficient controls (Fig. 8A), and all four Asn221-containing
proteins were unable to activate the classical complement pathway
to its terminal components (Fig. 8A). These findings were reca-
pitulated with the Cys309 mutants (Fig. 8B), including those pro-
teins shown to form multimers (e.g., D221N/N297A/N563A/
C575A against N297A/N563A/C575A). As previously shown by
other groups, we have identified mutants capable of forming
multimers (e.g., C309L and D221N/N563A/C575A) that avidly
bound C1q but were unable to fix C5b-9 when compared with
hexa-Fc (Fig. 8B) (33).
Asn221-based monomers and multimers exhibit complex
sialylation patterns
The structure of the N-glycan on the Fc of IgG Abs has been
shown to influence multiple receptor interactions. For example,
the interaction of IVIG with glycan receptors has been attrib-
uted to direct and/or indirect effects of N-glycan sialic acid on
the Fc (29, 34, 35). Therefore, we investigated the nature of the
N-glycans on the two panels of glycosylation- and cysteine-
deficient mutants by MALDI-TOF mass spectrometry–based
glycomic analysis (Fig. 9, Supplemental Fig. 2–4).
We previously demonstrated that N-glycans from both IgG1–Fc
and clinical IVIG preparations are dominated by biantennary
complex N-glycans with 0, 1, or 2 galactose residues Q:28(2). A mi-
nority of these complex structures are also monosialylated (2, 23).
Representative glycomic data are presented in Fig. 9 for N297A/
C575A and D221N/N297A/N563A/C575A.
In both samples, the spectra demonstrate a higher level of N-
glycan processing with enhanced levels of biantennary gal-
actosylation and sialylation. In addition, larger tri- and tetra-
antennary complex N-glycans are also observed, which can be
fully sialylated (for example, peaks at m/z 3776 and 4587).







Table II. Summary of mutants and their interactions with Fcg receptors
Fcg Receptors Complex Sialylated Glycans Detected FcgRI FcgRIIA FcgRIIB FcgRIIIA FcgRIIIB
C309L/N297A/N563A/C575A — — — — — —
IgG1-Fc — + — — — —
N297A/C575A + — — — — —
D221N/N297A/C575A +++ — — — — —
C309L/N297A/C575A +++ — — — — —
D221N/C309L/N297A/C575A +++ — — — — —
C575A 2/+ + — — — —
D221N/C575A +++ + — 2/+ — —
C309L/C575A 2/+ + — — — —
D221N/C309L/C575A + + — + — —
C309L/N563A/C575A — ++ — — +++ —
D221N/C309L/N297A/N563A/C575A ++ + — ++ 2/+ —
D221N/C309L/N563A/C575A + ++ — +++ ++ —
D221N/N297A/N563A/C575A +++ — — — — —
Hexa-Fc + ++ + 2/+ + —
D221N/N563A/C575A + ++ — — ++ —
C309L ++ ++ — — +++ —
N297A/N563A/C575A — ++ — +++ — —
N563A/C575A 2/+ ++++ — + ++++ —

































































































































and Asn-575 contained larger, more highly processed N-gly-
cans that are not observed on the IgG1–Fc control (Fig. 9 and
Supplemental Figs. 2–4). As predicted, no glycans could be
detected on the glycosylation-deficient double mutants
(N297A/N563A/C575A and C309L/N297A/N563A/C575A).
The Asn221 glycan imparts enhanced binding to influenza HA
To determine if any of the hypersialylated Fc mutants possessed
biologically useful properties, we investigated their binding to HA,
a prototypic viral sialic acid–binding ligand (Fig. 10A, 10B). We
used clinically available IVIG as a positive control because IVIG
F10
FIGURE 7. Binding of selected mutants
to FcgRs by Biacore surface plasmon res-
onance analysis. (A) Binding of C309L/
N297A/C575A, D221N/C309L/N297A/
C575A, C309L/N563A/C575A, D221N/
C309L/N563A/C575A, and monomeric Fc
control to human FcgRI (CD64). Curves
shown for molecules at 300, 150, and 75
nM, respectively. (B) Binding of the same
mutants to FcgRIIIA-Val176 (CD32A).
Curves shown for molecules at 8000, 4000,
and 2000 nM, respectively. Because of the
varying stoichiometry of the molecules
shown (Fig. 3 and Supplemental Fig. 1C),
an accurate determination of interaction
kinetics is not possible. Binding to FcgRs
from R&D Systems is illustrated, although
binding with receptors sourced from Sino
Biological gave nearly identical resultsQ:45 .

































































































































is known to contain high concentrations of IgG Abs against a
diverse range of influenza HAs (36).
As expected, IVIG bound strongly to recombinant HA from both
influenza A and B viruses (Fig. 10A, 10B). With the exception of
the aglycosylated mutants (C309L/N297A/N563A/C575A and
N297A/N563A/C575A) and the IgG1–Fc control, all the glycan-
modified Fc fragments bound recombinant HA from both group A
and B viruses. Binding was also reflected in the abundance of
FIGURE 8. Binding of the C309L and C575A mutants to complement. (A) Both the C309L/N563A/C575A and C309L/N297A/N563A/C575A mutants
bound C1q and permitted C5b-9 deposition. Insertion of Asn221 into both these mutants to create D221N/C309L/N563A/C575A and D221N/C309L/
N297A/N563A/C575A allows C1q deposition but prevented subsequent C5b-9 deposition. This shows that the presence of the Asn221 glycan while
allowing C1q to bind blocks subsequent downstream activation of the classical pathway. Mutants in which only the Asn297 glycan was removed, as in
C309L/N297A/C575A or D221N/C309L/N297A/C575A, were unable to bind C1q or fix C5b-9. (B) Binding of the C575A mutants to complement. With
the exception of D221N/N563A/C575A, the presence of Asn221 inhibited binding to C1q, although all Asn221-containing mutants including D221N/N563A/
C575A were unable to fix C5b-9. Error bars represent SD around the mean value; n = 2 independent experiments.

































































































































sialylated N-glycans of the mutant proteins (Supplemental Figs.
2–4). Thus, mutants containing Asn221 bound more strongly than
their equivalents in which Asn221 was absent (Fig. 10A, 10B).
Although binding to native inactivated influenza strain A New
Caledonia/20/99 virus (H1N1) was poorer than binding to either
recombinant HAs from influenza A (Shantou) or influenza B
(Florida), respectively, two mutants (D221N/C309L/N297A/
C575A and D221N/C575A) showed superior binding to the na-
tive virus compared with either IVIG or their equivalent mutants in
which Asn221 was absent (compare C575A with D221N/C575A)
(Fig. 10A, 10B).
Asn221-containing mutants inhibit hemagglutination
by influenza
To test if the binding to HA has any functional relevance, we used
the World Health Organization–based hemagglutination inhibition
protocol to quantify influenza-specific inhibitory titers of the
mutants that bound the native virus strongly (Fig. 10C). Both
D221N/C309L/N297A/C575A and D221N/C575A prevented
hemagglutination by New Caledonia/20/99 virus (H1N1) at con-
centrations as low as 0.1 mM and were demonstrably more ef-
fective than molar equivalents of either IVIG or anti-H1N1
polyclonal IgG.
In contrast, the equivalent molecules that lack Asn221
(i.e., C309L/N297A/C575A and C575A) failed to inhibit hem-
agglutination although partial inhibition was observed with the
C575A mutant at the highest concentrations in some experiments
(Fig. 10C). Hence, receptor binding of influenza A viruses is
competed out only by mutants in which Asn221 and Asn563 are
present. That both mutants run entirely as monomers by SEC-HPLC
(Supplemental Fig. 1C) shows that the disposition of the glycans at
the N terminus and C terminus of the Fc are more favorably ori-
entated for binding native viral HA in monomers than multimers.
Discussion
Many groups have postulated that multivalent Fc constructs have
potential for the treatment of immune conditions involving path-
ogenic Abs (2, 5, 37, 38), and a recent study has shown that
hexavalent Fcs can block FcgRs leading to their downmodulation
and prolonged disruption of FcgR effector functions both in vitro
and in vivo (39, 40). Hexameric Fcs have also been shown to
inhibit platelet phagocytosis in mouse models of idiopathic
thrombocytopenic purpura (39, 41).
Although disulfide-bonded hexameric Fcs may provide exciting
new treatment approaches to control autoimmune diseases, they are
more difficult to manufacture than smaller simpler Fc molecules.
Their beneficial effects must also be carefully balanced with the
acute risk of proinflammatory responses observed upon FcgR
crosslinking and the increased risk from infection or cancers due
to long-term immune suppression. These potential drawbacks with
multimeric Fcs led us to investigate if complex monomers may be
developed that retain the advantages of multimers (e.g., high-
avidity binding to low-affinity receptors) but that are also more
readily manufactured to scale.
Although Fc engineering by mutagenesis and/or direct modifi-
cation to the Asn297 glycan have yielded modified affinity and/or
selectivity for FcgRs (1, 18, 42–47), interactions with glycan re-
ceptors have largely been ignored despite a large body of literature
demonstrating their importance in controlling unwanted inflammation
(48–51). However, such approaches that show enhanced receptor
Table III. Summary of mutants and their interactions with complement and influenza HA
Complex
Sialylated















— + + — — — No
IgG1-Fc — + + — — — No
N297A/C575A + — — — 2/+ — n.d.
D221N/N297A/
C575A
+++ — — — ++ + n.d.
C309L/N297A/
C575A
+++ — — — +++ ++ No
D221N/C309L/
N297A/C575A
+++ — — ++++ +++ +++ Yes
C575A 2/+ 2/+ 2/+ — ++ + No
D221N/C575A +++ — — ++++ +++ ++ Yes
C309L/C575A 2/+ + 2/+ — + — No
D221N/C309L/
C575A
+ 2/+ 2/+ + + — n.d.
C309L/N563A/
C575A




++ + — + ++ + n.d.
D221N/C309L/
N563A/C575A
+ ++ — + ++ + n.d.
D221N/N297A/
N563A/C575A
+++ 2/+ — — + 2/+ n.d.
Hexa-Fc + ++
+





— — ++ + n.d.
C309L ++ ++
+
— — ++ 2/+ n.d.
N297A/N563A/
C575A
— + + — — — No
N563A/C575A 2/+ ++ 2/+ — — — n.d.

































































































































interactions via mutations introduced into full-length IgG moleculesQ:29
(3, 52, 53) may not necessarily be predictive a priori in the context of
either Fc multimers or their Fc fragments (24, 39).
Furthermore, reported Fcmutations or glycan modifications have
mostly focused on the conserved Asn297 glycan that is largely
buried within the Fc (4, 17–20), and thus monomeric IgG1 is
unable to interact with a broad range of glycan receptors
(Fig. 11A). Although Siglec-2 (35), DC-SIGN (2, 54, 55), DCIR
(34), and FcRL5 (2, 56) have all recently been shown to be ligands
for IVIG, these interactions may also stem from specific Fab-
mediated binding (57). Thus, glycosylation of intact IgG is
known to be critically important, but the relative contribution of
the Fc, Fab, and/or their attached glycans, together with the
identity of the salient receptors involved in IVIG efficacy, remain
controversial.
We took an alternative approach to glycan modification by in-
troducing, in various combinations, two additional N-linked gly-
cosylation sites (Asn221 and Asn563) into our hexa-Fc (2, 24). To
investigate the effects of this additional glycosylation, hexa-Fc
was further mutated to remove one (Fig. 1) or both of the cyste-
ine residues (Cys309 and Cys575) (Fig. 2) that are required for
interdisulfide bond formation between individual Fc moieties in
hexa-Fc. This approach yielded complex glycosylated molecules
(Figs. 3, 9 and Supplemental Figs. 2–4), including the monomeric
D221N/C309L/C575A mutant that has all three glycans attached
and which showed improved binding to FcgRIIB, DC-SIGN, and
DCIR; these receptors being implicated in the efficacy of IVIG
(Table I) (8, 17, 20, 58, 59). The triglycan mutant (D221N/C309L/
C575A) also bound more strongly and broadly to all the glycan
receptors investigated, including receptors recently implicated in
IVIG efficacy [e.g., CD23 (60), CD22 (35), and DCIR (clec4a)
(34)] when compared with monoglycosylated (e.g., IgG1-Fc) or
nonglycosylated (C309L/N297A/N563A/C575A) controls (Fig. 4,
Table I).
The observed binding to CD22 was particularly surprising as this
receptor prefers a-2,6 linked neuraminic acid and not a-2,3
linkages attached by CHO-K1 cells, although proximity-labeling
experiments have recently shown that glycan-independent inter-
actions of CD22/Siglec-2 with Ig in the BCR is possible (61).
We also observed marked binding of D221N/C309L/C575A to
dectins (Fig. 4), receptors that more typically recognize b-1,3-
glucans expressed by fungal pathogens (62). Although dectin-1 is
known to bind variably glycosylated human tetraspanins CD37
and CD63 (63), the anti-inflammatory activity of IgG1 immune
complexes may be mediated by Fc galactosylation and associa-
tions with dectin-1 and FcgRIIB (64).
The insertion of multiple glycan sites into the Fc, in particular at
Asn221, enables new receptor interactions that are not possible
with solely Asn297-directed approaches (Fig. 11A). For example,
we generated the di-glycan D221N/C309L/N297A/C575A mutant
that displayed marked binding to Siglec-1 and Siglec-4 (MAG),
both receptors being clinically implicated in the control of neu-
ropathy (15, 25). This mutant showed no observable binding to
either FcgRs or complement proteins (Tables II, III) yet was
F11
FIGURE 9. MALDI-TOF mass spectrometry profiles of permethylated N-glycans from N297A/C575A and D221N/N297A/N563A/C575A IgG1–Fc
mutants. The data were acquired in the positive ion mode to observe [M + Na]+ molecular ions. All the structures are based on composition and knowledge
of biosynthetic pathways. Structures shown outside a bracket have not had their antenna location unequivocally defined.

































































































































FIGURE 10. Impact of Fc glycosylation. (A) ELISA binding of the C309L/C575A panel and (B) the C575A panel of Fc glycosylation mutants to HA. (C)
Impact of Fc glycosylation on hemagglutination inhibition. A constant amount of influenza A New Caledonia/20/99 virus H1N1 was incubated with titrated
amounts of the Fc glycan mutants and added to human O+ erythrocytes that were then allowed to sediment at room temperature for 1 h. Nonagglutinated
RBCs form a small halo. Dashed lines indicate splicing from the original plate images deposited with the journal to allow for clearer visualization of
pelleted cells in each duplicated well. n = 2 independent experiments.

































































































































highly effective at blocking hemagglutination by influenza A virus
(Fig. 10C).
As glycan-mediated binding is essential for the influenza virus to
infect cells of the respiratory tract, mutations in HA that lead to loss
of receptor binding are unlikely to survive any neutralizing Abs
induced during an immune response (Fig. 11B). Modeling of the
D221N/C575A mutant shows that the distance from the N-
terminal to the C-terminal tips of the Fc is ∼60 A˚ (Fig. 11B),
which is the same distance between the sialic acid–binding do-
mains on the HA trimer (65). The Asn221 and Asn563 sugars lo-
cated at the tips of the Fc are not constrained by their location
within the Fc, as with Asn297, and would therefore be expected to
be highly mobile and flexible with respect to searching out the
HA-binding pocket.
Alternative anti-influenza therapeutic strategies are urgently
needed. The use of IVIG during the 2009 and 1918 pandemics
reduced mortality from influenza by 26 and 50%, respectively (66,
67), and a recent randomized, placebo-controlled study suggests
these figures may be improved by enhancing influenza-specific
Abs in IVIG (Flu-IVIG) preparations (36). As Flu-IVIG is man-
ufactured in advance of future epidemics, there may be modest or
no neutralizing activity against emerging strains. Combinations of
Flu-IVIG or neuraminidase inhibitor drugs with Fc sialic acid–
binding domain blockers may enhance the efficacy of Flu-IVIG or
neuraminidase inhibitor-based medicines. Neither the D221N/
C575A nor D221N/C309L/N297A/C575A mutants that inhibited
hemagglutination so effectively (Fig. 10C) bind FcgRIIIA (Fig. 6
and Table II) and would thus not be expected to interfere with
FcgRIIIA-dependent Ab-dependent cellular cytotoxicityQ:30 toward
influenza-infected cells by neutralizing IgG present in Flu-IVIG.
As well as direct HA binding, the molecules may shield sialic
acid receptor binding sites on epithelial cells or act as decoy re-
ceptors through receptor mimicry, thereby preventing binding of
the virus to epithelial target cells. Similarly, being rich in sialic
acid, the molecules may also act as decoy substrates for neur-
aminidase. Intranasal delivery of Fc fragments may therefore be
feasible, as Fc-fused IL-7 can provide long-lasting prophylaxis
against lethal influenza virus after intranasal delivery (68). We
have previously shown that Fc multimers can bind the neonatal
Fc receptor (FcRn) (69). Thus, binding to the FcRn may act to
increase the residence time of Fc blockers delivered to the lung
(70, 71).
A potential drawback to the hypersialylation approach with
respect to blocking HA may be the susceptibility of Fc glycans to
viral neuraminidase. Although neuraminidase from Clostridium
perfringens could catalyze the hydrolysis of sialic acid residues
from our soluble Fc fragments and thus block interactions with
glycan receptors (Supplemental Fig. 1B), it remains to be tested if
HA-bound Fcs are susceptible to catalysis by the influenza neur-
aminidase. We believe that metabolic oligosaccharide engineering
with alkyne sialic acids could create neuraminidase-resistant Fc
blockers (72).
In another example, multiple mutants were shown to bind DEC-
205 (Figs. 4, 5, Table I), the major endocytic receptor expressed by
dendritic cells, which suggests that these constructs may be useful
for the targeted delivery of Ags in vaccines. Current approaches to
deliver Ag to DEC-205 rely on DEC-205–specific delivery, often
with Ags fused to anti–DEC-205 mAbs (73–75), whereas ap-
proaches that target multiple dendritic cell Q:31receptors, including
DEC-205, may make for more effective Ag delivery.
To be useful in vaccines, an Ag must cluster through the binding of
multiple Fc regions in near-neighbor interactions with multiple low-
affinity FcgRs (76), and in particular FcgRIIA, FcgRIIB, and
FcgRIIIA (76–78). As described above, we generated multimers with
differential binding to either FcgRIIB (e.g., N297A/N563A/C575A),
FcgRIIIA (e.g., C309L and D221N/N563A/C575A), or with a ca-
pability to bind both FcgRIIB and FcgRIIIA (e.g., N563A/C575A).
Multimers formed by the N563A/C575A or C309L/N563A/C575A
mutants may be particularly relevant, as these were also able to bind
type 2 glycan receptors and activate the complement cascade, both
implicated in the efficacy of vaccines (5).
We also created molecules disrupted for covalent bonding (the
double cysteine knockouts) that formed multimers in solution
through noncovalent tailpiece clustering (e.g., C309L/N563A/
C575A and D221N/C309L/N563A/C575A) that showed en-
hanced interactions with FcgRs, in particular FcgRIIIA (Figs. 6,
7). Whether these will be more effective than covalently stabilized
Fcs (e.g., N563A/C575A) at enhancing FcgRIIIA-mediated ef-
fector functions, in for example therapeutic mAbs or Fc-fusion
therapies/vaccines, remains to be determined.
FIGURE 11. Model showing proposed cis interactions of the triglycan D221N/C575A mutant with (A) glycan receptors or (B) influenza HA. The glycan
at Asn297 in the wild-type IgG1 Fc is buried and unable to interact directly with receptors. However, monomers with glycans located at both the N terminus
and C terminus of the Fc (Asn221 and Asn563), as in D221N/C575A, are exposed and therefore allow crosslinking of sialic acid–dependent receptors
(including Siglec-1 or HA) (48).

































































































































As summarized in Tables I–III, we identified the following: 1)
mutant Fc molecules that are capable of binding C1q and acti-
vating complement but that show little or no detectable interaction
with either FcgRs or glycan receptors; 2) molecules with en-
hanced activation of complement, improved binding to FcgRs, and
little engagement of glycan receptors; 3) molecules with enhanced
binding to C1q but little C5b-9 deposition that retain interaction
with both Fcg and glycan receptors; and 4) monomeric molecules
with enhanced binding to a subset of sialic acid–dependent glycan
receptors, in particular Siglec-1, Siglec-4, and HA, with little or
no interaction with either FcgRs or complement.
Consequently, by adding or removing glycosylation and/or
disulfide-bonding sites within our original hexameric Fc plat-
form (2, 5, 24), new repertoires of desirable binding attributes can
be made. These molecules may be useful in the control of other
pathogens, including Newcastle disease virus, group B strepto-
cocci, Streptococcus pneumoniae, and Mycoplasma genitalium, in
which sialic acid–dependent interactions are also crucially im-
portantQ:32 (79).
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subsequent references were renumbered. Please check the text citations of Refs. 54 and all
subsequent references against the References list to ensure that the renumbering was done properly.
30—Please confirm that “ADCC” was expanded correctly in the sentence beginning “Neither the
D221N/C575A. . .” or amend as needed.
31—Please confirm that “DC” was expanded correctly in the sentence beginning “Current approaches
to. . .” or amend as needed.
32—A response to this query is REQUIRED: Please confirm that all potential conflicts of interest have
been disclosed.
33—Please confirm that “NIAID” was expanded correctly in the sentence beginning “The following
reagents. . .” in the Acknowledgments or amend as needed.
34—Please confirm that “SPR” was expanded correctly in the sentence beginning “We thank
Abzena. . .” in the Acknowledgments and throughout or amend as needed.
35—Please confirm that all publication details for Ref. 17 are correct, including for the erratum.
36—The original Ref. 25 was a duplicate of Ref. 15, so the duplicate reference was deleted, and the
subsequent references were renumbered. Please check the text citations of Ref. 25 and all
subsequent references against the References list to ensure that the renumbering was done properly.
37—The original Ref. 37 was a duplicate of Ref. 2, so the duplicate reference was deleted, and the
subsequent references were renumbered. Please check the text citations of Refs. 37 and all
subsequent references against the References list to ensure that the renumbering was done properly.
38—Please replace “No Title” with the title and date for the conference in Ref. 41 or delete “No Title,”
and provide any other details that are needed so a reader can access this material.
39—The original Ref. 54 was a duplicate of Ref. 3, so the duplicate reference was deleted, and the
subsequent references were renumbered. Please check the text citations of Refs. 54 and all
subsequent references against the References list to ensure that the renumbering was done properly.
40—Please confirm that all publication details for Ref. 59 are correct, including for the erratum.
41—If your article includes figures, please check the figures in your proof carefully. If any changes are
needed, please provide a revised figure file.
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42—In the legend for Fig. 2, please check the sentence beginning “Schematic showing the. . .” to ensure
that the edits preserve your intent.
43—In the legend for Fig. 3, please provide the stain(s) used, if applicable.
44—Please confirm or amend the edits made to “Sigma-Aldrich” in the sentence beginning “All proteins
were. . .” in the legend for Fig. 3F.
45—Please add an explanation of the colors used in Fig. 7 to the figure legend if it would be appropriate to
do so.
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